Long-term stability of acquired drug resistance and resistance associated mutations in the fungal pathogen

Candida glabrata / genetics Antifungal Agents / pharmacology Drug Resistance, Fungal / genetics Mutation Fluconazole / pharmacology Microbial Sensitivity Tests Anidulafungin / pharmacology Phenotype Drug Resistance, Multiple, Fungal / genetics
Nakaseomyces glabratus (Candida glabrata) aneuploidy drug resistance stability microevolution mutations

Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2024
Historique:
received: 12 04 2024
accepted: 25 06 2024
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 30 7 2024
Statut: epublish

Résumé

The limited number of available antifungal drugs and the increasing number of fungal isolates that show drug or multidrug resistance pose a serious medical threat. Several yeast pathogens, such as

Identifiants

DOI: 10.3389/fcimb.2024.1416509 PMID: 39077431 PMC: PMC11284152
pubmed: 39077431
doi: 10.3389/fcimb.2024.1416509
pmc: PMC11284152
doi:

Substances chimiques

Antifungal Agents 0
Fluconazole 8VZV102JFY
Anidulafungin 9HLM53094I

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1416509

Informations de copyright

Copyright © 2024 Ksiezopolska, Schikora-Tamarit, Carlos Nunez-Rodriguez and Gabaldón.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Ewa Ksiezopolska (E)

Department of Life Sciences, Barcelona Supercomputing Centre (BSC-CNS), Barcelona, Spain.
Department of Mechanisms of Disease, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.

Miquel Àngel Schikora-Tamarit (MÀ)

Department of Life Sciences, Barcelona Supercomputing Centre (BSC-CNS), Barcelona, Spain.
Department of Mechanisms of Disease, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.

Juan Carlos Nunez-Rodriguez (J)

Department of Life Sciences, Barcelona Supercomputing Centre (BSC-CNS), Barcelona, Spain.
Department of Mechanisms of Disease, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.

Toni Gabaldón (T)

Department of Life Sciences, Barcelona Supercomputing Centre (BSC-CNS), Barcelona, Spain.
Department of Mechanisms of Disease, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
Department of CIBERinfect, Centro Investigación Biomédica En Red de Enfermedades Infecciosas, Barcelona, Spain.

Articles similaires

Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses.

Megan Cole, Panayiotis Anastasiou, Claudia Lee et al.
1.00
T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis

Prevalence and implications of fragile X premutation screening in Thailand.

Areerat Hnoonual, Sunita Kaewfai, Chanin Limwongse et al.
1.00
Humans Fragile X Mental Retardation Protein Thailand Male Female

More T cell receptors to the RAScue in cancer?

Eric Tran
1.00
Humans Receptors, Antigen, T-Cell Proto-Oncogene Proteins p21(ras) Pancreatic Neoplasms T-Lymphocytes

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Champignons › Levures › Candida › Candida glabrata › Long-term stability of acquired drug...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antifongiques › Long-term stability of acquired drug...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance microbienne aux médicaments › Résistance des champignons aux médicaments › Long-term stability of acquired drug...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Long-term stability of acquired drug...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Triazoles › Fluconazole › Long-term stability of acquired drug...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Long-term stability of acquired drug...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Peptides cycliques › Échinocandines › Anidulafungine › Long-term stability of acquired drug...
questionsmedicales.fr › Phénomènes génétiques › Phénotype › Long-term stability of acquired drug...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Multirésistance aux médicaments › Multirésistance des champignons aux médicaments › Long-term stability of acquired drug...